Pfizer is a research-based pharmaceutical company engaged in the wellness, prevention and treatment for diseases across a broad range of therapeutic areas. The company operates through Innovative Health and Established Health businesses.
Innovative Health encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Establish Health includes Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. In 2015, Pfizer recorded sales of USD 48.85 billion, a decrease by 1.5% compared to decrease of 3.8% in 2014. This can be attributed to the impact of acquisitions and divestitures on global operations. In 2016, Pfizer stood at USD 39.2 billion, total increase of 13%, as compared to 2015 fiscal nine months sales of $34.8 billion. The fiscal third quarter (Q3) sales were USD 13 billion an increase of 8% compared to 2015 Q3 sales. The high growth in 2016 vs 2015 can be attributed the inclusion of nine months of revenues from legacy Hospira global operations in the first nine months of 2016 compared to the inclusion of only one month in the first nine months of 2015, along with the continued growth from key brands including Ibrance, Lyrica, Xeljanz and Chantix/Champix and Consumer Healthcare, all primarily in the U.S., as well as Eliquis globally
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.